Delivery of allogeneic bone marrow-derived MSCs not checked
BioCardia, Inc. · allogeneic NK1R+MSC
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- ARDS, Human
- Main trialPhase 1
- “Allogeneic culture-expanded bone marrow-derived human mesenchymal stem cells (MSC) are the subject of the current study as they are supported by preclinical and clinical data for potential to provide a safe and effective treatment for patients with acute respiratory distress.”In the company’s words, NCT05491681 on ClinicalTrials.gov
- Other names
- allogeneic NK1R+MSC
Other drugs for ARDS, Human
- APC-0101Aerogen Pharma Limited · Phase 3
- TozorakimabAstraZeneca · Phase 3
- ExoFloDirect Biologics, LLC · Phase 3
- Aerosolized CalfactantONY · Phase 3
- LEAF-4L6715LEAF4Life, Inc. · Phase 3
- STSA-1002Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Withdrawn | 4 Jan 2026 | AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026